Addex Therapeutics (NASDAQ: ADXN) files Form 6-K, links press release to F-3 and S-8

Rhea-AI Filing Summary

Addex Therapeutics Ltd furnished a Form 6-K as a foreign private issuer for September 2025. The company reports that on September 23, 2025 it issued a press release, attached as Exhibit 99.1. The press release is incorporated by reference into its existing Form F-3 and Form S-8 registration statements.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2025

Commission File Number: 001-39179

Addex Therapeutics Ltd
(Translation of registrant's name into English)

Chemin des Mines 9,
CH-1202 Geneva,
Switzerland
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

On September 23, 2025, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

(c) Exhibit 99.1. Press release dated September 23, 2025

INCORPORATION BY REFERENCE

Exhibit 99.1 to this Report on Form 6-K shall be deemed to be incorporated by reference into the registration statement on Form F-3 (Registration No. 333-255089) of Addex Therapeutics Ltd and the registration statement on Form S-8 (Registration No. 333-255124 and No. 333-272515) of Addex Therapeutics Ltd (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		Addex Therapeutics Ltd
		(Registrant)
Date: September 23, 2025		/s/ Tim Dyer
		Tim Dyer
		Chief Executive Officer

EXHIBIT INDEX

Exhibit Number		Description
99.1		Press release dated September 23, 2025

FAQ

What does Addex Therapeutics (ADXN) report in this September 2025 Form 6-K?

Addex Therapeutics reports that it issued a press release on September 23, 2025. The Form 6-K primarily serves to furnish this release to investors and formally link it to existing SEC registration statements through incorporation by reference.

What is Exhibit 99.1 in Addex Therapeutics (ADXN) September 2025 Form 6-K?

Exhibit 99.1 is a press release dated September 23, 2025. The Form 6-K states that this press release is attached as the sole exhibit and is incorporated by reference into Addex Therapeutics’ Form F-3 and Form S-8 registration statements.

How is the September 23, 2025 press release used in Addex Therapeutics (ADXN) SEC filings?

The press release is incorporated by reference into Addex Therapeutics’ Form F-3 registration statement No. 333-255089 and Form S-8 registration statements Nos. 333-255124 and 333-272515. This means the release becomes part of those registration statements from the Form 6-K filing date.

Which annual report form does Addex Therapeutics (ADXN) use according to this Form 6-K?

Addex Therapeutics indicates it files annual reports on Form 20-F. The checkbox section specifies Form 20-F, confirming it follows the standard annual reporting framework used by many foreign private issuers listed in U.S. markets.

Who signed the September 2025 Addex Therapeutics (ADXN) Form 6-K?

The Form 6-K was signed on behalf of Addex Therapeutics Ltd by Tim Dyer, Chief Executive Officer. His electronic signature appears on the signature block dated September 23, 2025, indicating executive authorization of the furnished information and exhibit.